Works matching IS 08909091 AND DT 2024 AND VI 38
Results: 106
3 Things You Should Know About Hemolytic Anemias.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 12, p. 482
- By:
- Publication type:
- Article
3 Things You Should Know About Immunotherapy in DLBCL.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 12, p. 478
- By:
- Publication type:
- Article
Experts' Perspectives on Pancreatic Cancer Treatment.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 12, p. 476
- Publication type:
- Article
Efficacy and Safety of Zolbetuximab in Gastric Cancer.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 12, p. 472, doi. 10.46883/2024.25921031
- By:
- Publication type:
- Article
Zolbetuximab's Impact on Gastric/GEJ Adenocarcinoma.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 12, p. 470
- Publication type:
- Article
Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 12, p. 462, doi. 10.46883/2024.25921032
- By:
- Publication type:
- Article
Approaching End-of-Life Discussions With Directness and Compassion.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 12, p. 458
- By:
- Publication type:
- Article
Assessing 2024 Oncology Advances and Looking Ahead.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 12, p. 457
- By:
- Publication type:
- Article
Precision Medicine in NSCLC: The Power of Molecular Testing.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 11, p. 444
- By:
- Publication type:
- Article
Casting a Wide NET: When Is the Optimal Time for <sup>177</sup>Lu-Dotatate Treatment?
- Published in:
- Oncology (08909091), 2024, v. 38, n. 11, p. 442, doi. 10.46883/2024.25921029
- By:
- Publication type:
- Article
3 Things You Should Know About Biomarkers in DLBCL.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 11, p. 438
- By:
- Publication type:
- Article
Implementing a Multidisciplinary Lifestyle Medicine Clinic for Cancer Survivorship.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 11, p. 421, doi. 10.46883/2024.25921030
- By:
- Publication type:
- Article
Taste Adverse Effects.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 11, p. 418
- Publication type:
- Article
Assessing NP Roles in Talquetamab Treatment for Multiple Myeloma.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 11, p. 416
- By:
- Publication type:
- Article
Quadruplet Therapy Shows Benefit for Newly Diagnosed Multiple Myeloma.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 11, p. 413
- By:
- Publication type:
- Article
The Hidden Danger: Unveiling the Connection Between Multiple Myeloma and Pleural Effusion.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 11, p. 410, doi. 10.46883/2024.25921028
- By:
- Publication type:
- Article
Uterine Transposition Surgery Offers QOL Improvement Through Fertility Preservation.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 11, p. 407
- By:
- Publication type:
- Article
Gender Equity in Hematology/Oncology Have We Made Any Progress?
- Published in:
- Oncology (08909091), 2024, v. 38, n. 11, p. 406
- By:
- Publication type:
- Article
The Evolving Landscape of Prostate Cancer Management: BRCA Testing and ctDNA as Diagnostic Tools and PSMA-Imaging and -Targeted Approaches.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 10, p. 387
- By:
- Publication type:
- Article
Linvoseltamab Still Efficacious Despite CRL in Multiple Myeloma.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 10, p. 384
- By:
- Publication type:
- Article
Expert Commentary on the Product Pro? le of Lazertinib in NSCLC.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 10, p. 381
- By:
- Publication type:
- Article
Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 10, p. 376, doi. 10.46883/2024.25921027
- By:
- Publication type:
- Article
Cancer Rehabilitation Medicine: "Bridging the Gap" With Supportive Care.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 10, p. 372
- By:
- Publication type:
- Article
Breast Cancer Breakthroughs: 2024 ESMO Highlights.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 10, p. 371
- By:
- Publication type:
- Article
Starting at the Front Line in Metastatic Pancreatic Cancers: As New Options Emerge, How Do You Select and Sequence?
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 352
- By:
- Publication type:
- Article
Determining Administration of BCMA, T-Cell Engagers in R/R Multiple Myeloma.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 349
- By:
- Publication type:
- Article
Manageable AEs Noted in Belzutifan for Advanced RCC.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 348
- Publication type:
- Article
Real-World Data Showcase Survival Outcomes After Immunotherapy/TKI Regimens in RCC.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 348
- By:
- Publication type:
- Article
Multimodal AI Approach May Predict Outcomes in Renal Cell Carcinoma.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 348
- Publication type:
- Article
Nivolumab Combo May Show Long-Term Benefits in Advanced RCC.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 347
- By:
- Publication type:
- Article
Expert Commentary on the Product Profile of Tisotumab Vedotin in Cervical Cancer.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 345
- By:
- Publication type:
- Article
Multidisciplinary Team Meetings: Barriers to Implementation in Cancer Care.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 339, doi. 10.46883/2024.25921026
- By:
- Publication type:
- Article
Reconsidering REMS Mandate May Improve CAR T-Cell Therapy Accessibility.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 336
- By:
- Publication type:
- Article
2024 Statistics May Impact Next Decade of Cancer Treatment.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 335
- By:
- Publication type:
- Article
Publisher's Note.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 332
- By:
- Publication type:
- Article
Quadruplet Therapy May Be the New Frontline SOC in Multiple Myeloma.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 8, p. 317
- By:
- Publication type:
- Article
Expert Commentary on the Product Profile of Tislelizumab in Advanced Esophageal Cancer [including commentary by Krystal Preston].
- Published in:
- Oncology (08909091), 2024, v. 38, n. 8, p. 315
- By:
- Publication type:
- Article
Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid Leukemia.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 8, p. 311, doi. 10.46883/2024.25921025
- By:
- Publication type:
- Article
AI Use May Improve Treatment Outcomes in Prostate Cancer.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 8, p. 309
- By:
- Publication type:
- Article
Epcoritamab in Relapsed/Refractory Follicular Lymphoma.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 8, p. 306
- Publication type:
- Article
Exercise Treatment as Part of Multidisciplinary Whole Person Care in Oncology.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 8, p. 305
- By:
- Publication type:
- Article
Highlights and Updates From ASCO 2024.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 7, p. 261
- By:
- Publication type:
- Article
An Embarrassment of Riches: Treatment Sequencing in Gastrointestinal Cancers.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 7, p. 287
- Publication type:
- Article
Liso-Cel in Relapsed/Refractory Mantle Cell Lymphoma.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 7, p. 272
- Publication type:
- Article
Expert Commentary on the Product Profile of Fruquintinib in Metastatic CRC.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 7, p. 269
- Publication type:
- Article
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 7, p. 264, doi. 10.46883/2024.25921024
- By:
- Publication type:
- Article
New Combination-Based Approaches to NDMM.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 6, p. 244
- Publication type:
- Article
MULTIDISCIPLINARY CARE.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 6, p. 241
- Publication type:
- Article
Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 6, p. 239, doi. 10.46883/2024.25921023
- By:
- Publication type:
- Article
Amivantamab Plus Chemotherapy in EGFR Exon 20+ NSCLC.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 6, p. 237
- Publication type:
- Article